The PARSC Trial, a Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint

Publication Name: ASCO 2011 Poster

Author(s): R. Salazar, R. Rosenberg, M. Lutke Holzik, J. Marshall4 , J. J. M. Van Der Hoeven, B. Glimelius, F. Bibeau, L. Stork-Sloots

Background: An 18-gene expression profile, ColoPrint, has been developed for identifying CC patients more likely to develop recurrent disease and who would be candidates for adjuvant chemotherapy. The gene signature was validated in in-silico datasets and independent patient cohorts of stage … Continued